N,1,5-三甲基-1H-吡唑-3-胺 | 646506-40-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: N,1,5-三甲基-1H-吡唑-3-胺
• 中文别名: N,1,5-三甲基-3-氨基-1H-吡唑
• 英文名称: N,1,5-Trimethyl-1H-pyrazol-3-amine
• 英文别名: N,1,5-trimethylpyrazol-3-amine
• CAS: 646506-40-3
• 化学式: C₆H₁₁N₃
• 分子量: 125.17
• InChiKey: AQUXBPZGVWSPHB-UHFFFAOYSA-N

物化性质

• 沸点：
  234 ºC
• 密度：
  1.06
• 闪点：
  96 ºC

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  29.8
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES<br/>[FR] INGÉNOL-3-ACYLATES III ET INGÉNOL-3-CARBAMATES
  申请人：LEO PHARMA AS

  公开号：WO2012083953A1

  公开（公告）日：2012-06-28

  The invention relates to compounds of general formula I wherein R is heteroaryl optionally substituted by R7; or R is heterocycloalkyl or heterocycloalkenyl, optionally substituted by R8; or R is X wherein X is -NR11R12; and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use -alone or in combination with one or more other pharmaceutically active compounds- in therapy, for preventing, treating or ameliorating diseases or conditions responsive to stimulation of neutrophil oxidative burst, responsive to stimulation of keratinocyte IL-8 release or responsive to induction of necrosis.

  该发明涉及一般式I的化合物，其中R为杂环芳基，可选择地由R7取代；或R为杂环烷基或杂环烯基，可选择地由R8取代；或R为X，其中X为-NR11R12；以及其在治疗中的药物可接受的盐、水合物或溶剂合物，用于单独使用或与一个或多个其他药用活性化合物结合在一起，用于预防、治疗或改善对中性粒细胞氧化爆发的刺激响应、对角质细胞IL-8释放的刺激响应或对坏死诱导的刺激响应的疾病或症状。
• Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
  申请人：Devasthale Pratik

  公开号：US20060264457A1

  公开（公告）日：2006-11-23

  Compounds are provided having the formula (I) wherein R, X, Y, Z, A and n are as defined herein, which are inhibitors of dipeptidyl peptidase IV and thus are useful in treating diabetes and related diseases.

  提供的化合物具有以下式(I)的结构，其中R、X、Y、Z、A和n的定义如本文所述，这些化合物是二肽基肽酶IV的抑制剂，因此在治疗糖尿病和相关疾病方面是有用的。
• [EN] NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES.<br/>[FR] NOUVEAUX COMPOSÉS UTILES POUR LE TRAITEMENT DE MALADIES DÉGÉNÉRATIVES ET INFLAMMATOIRES
  申请人：GALAPAGOS NV

  公开号：WO2010010188A1

  公开（公告）日：2010-01-28

  Novel [l,2,4]triazolo[l,5-a]pyridine compounds are disclosed that have a formula represented by the Formula I. The compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non- limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g. diseases involving the anabolic stimulation of chondrocytes), congenital cartilage malformations, diseases associated with hypersecretion of IL6 and transplantation rejection (e.g. organ transplant rejection) and proliferative diseases.

  揭示了具有由公式I表示的化学式的新型[l,2,4]三唑[1,5-a]吡啶化合物。这些化合物可以制备为药物组合物，并可用于预防和治疗包括人类在内的哺乳动物的各种疾病，例如涉及软骨降解、骨骼和/或关节降解的疾病，例如骨关节炎；以及涉及炎症或免疫反应的疾病，如克罗恩病、类风湿性关节炎、牛皮癣、过敏性气道疾病（如哮喘、鼻炎）、儿童特发性关节炎、结肠炎、炎性肠病、内毒素驱动的疾病状态（如旁路手术后的并发症或慢性内毒素状态导致的慢性心力衰竭等）、涉及软骨周转障碍的疾病（例如涉及软骨细胞合成促进的疾病）、先天软骨畸形、与IL6过度分泌和移植排斥有关的疾病（例如器官移植排斥）和增生性疾病。
• Large conductance calcium-activated k channel opener
  申请人：Imanishi Yasuhiro

  公开号：US20070060629A1

  公开（公告）日：2007-03-15

  The present invention provides a large conductance calcium-activated K channel opener comprising a compound of the formula (I): wherein R 1 and R 3 are each sulfonamide, carbamoyl, acyl, amino, and the like, m and n are each 0 to 2, R 2 and R 4 are each cyano, nitro, hydroxyl, an alkoxy, a halogen, or an alkyl, Ring A is benzene or a heterocyclic ring, Ring B is benzene, a heterocyclic ring, a cycloalkane etc, and Ring Q is pyrazole or isoxazole, or a pharmaceutically acceptable salt thereof as an active ingredient.

  本发明提供了一种大导电性钙激活K通道开放剂，其包括以下式子（I）的化合物：其中R1和R3各自为磺酰胺基，氨基甲酰基，酰基，氨基等，m和n各自为0到2，R2和R4各自为氰基，硝基，羟基，烷氧基，卤素或烷基，环A为苯环或杂环，环B为苯环，杂环，环己烷等，环Q为吡唑环或异噁唑环，或其药学上可接受的盐作为活性成分。
• Inhibitors of Janus Kinases
  申请人：Young Jonathan R.

  公开号：US20090306071A1

  公开（公告）日：2009-12-10

  The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3 TYK2 and PDK1 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer.

  本发明提供了一种抑制四种已知哺乳动物JAK激酶（JAK1、JAK2、JAK3和TYK2）和PDK1的化合物。本发明还提供了包含这种抑制剂化合物的组合物，以及通过向需要治疗骨髓增生性疾病或癌症的患者施用该化合物来抑制JAK1、JAK2、JAK3、TYK2和PDK1活性的方法。